Thompson Davis & Co’s Standard BioTools LAB Stock Holding History

Thompson Davis & Co’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-250	Closed	-$1K	–	711
2018 Q1	$1K	Buy	+250	New	+$1.64K	﹤0.01%	603
2014 Q4	–	Sell	-750	Closed	-$18K	–	1212
2014 Q3	$18K	Hold	750	–	–	0.02%	501
2014 Q2	$22K	Buy	750 +125	+20%	+$4K	0.03%	377
2014 Q1	$28K	Buy	625 +125	+25%	+$5.5K	0.05%	338
2013 Q4	$19K	Buy	+500	New	+$14.7K	0.03%	356

Other funds holding LAB

LCS

Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

HVC

Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return

Thompson Davis & Co's LAB Position: Q2 2018 in Review

Thompson Davis & Co sold out of Standard BioTools (LAB) in Q2 2018, closing a stake of 250 shares — an estimated $1K sold.

Thompson Davis & Co first reported a position in LAB in Q4 2013 and held it in 5 quarters. The position peaked at $28K in Q1 2014. 84 funds tracked by Wall St. Rank hold LAB as of Q2 2018.

Thompson Davis & Co reported no remaining Standard BioTools position as of Q2 2018 after selling out during the quarter.
Thompson Davis & Co sold 250 Standard BioTools shares in Q2 2018, an estimated $1K.
Thompson Davis & Co first reported a position in Standard BioTools in Q4 2013 and held it in 5 quarters.
Thompson Davis & Co's Standard BioTools position peaked at $28K in Q1 2014.
84 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2018.

Based on Thompson Davis & Co's 13F filing for Q2 2018, filed 3 Aug 2018.